Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation

• Published in: Toxicology mechanisms and methods Vol. 33; no. 3; pp. 197 - 205
• Main Authors: Tagawa, Kouji, Maruo, Yoshihiro, Mimura, Yu, Ikushiro, Shinichi
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 24.03.2023
• Subjects: Camptothecin - metabolism; Camptothecin - toxicity; Diarrhea - chemically induced; drug toxicity; glucuronidation activities; Glucuronosyltransferase - genetics; Glucuronosyltransferase - metabolism; Humans; Irinotecan; Neutropenia - chemically induced; UDP-glucuronosyltransferase 1; variant; glucuronidation activities; variant; Irinotecan; UDP-glucuronosyltransferase 1; drug toxicity
• ISSN: 1537-6516; 1537-6524; 1537-6524
• DOI: 10.1080/15376516.2022.2109229

The adverse effects (diarrhea and neutropenia) of irinotecan (7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin) are associated with genetic variants of uridine diphosphate glucuronosyltransferase 1A subfamilies (UGT1As). UGT1As are enzymes that metabolize the active form of irinotecan, 7-ethyl-10 hydroxycamptothecin (SN-38), by glucuronidation in the liver. They are widely known as predictive factors of severe adverse effects, such as neutropenia and diarrhea. Some studies have suggested that variants of UGT1As affect SN-38 glucuronidation activities, thus exerting severe adverse effects. We aimed to identify UGT1A isoforms that show SN-38 glucuronidation activity and determine the relationship between UGT1A variants and SN-38 glucuronidation in vitro. We found that UGT1A1 and UGT1A6-UGT1A10 displayed SN-38 glucuronidation activity. Among these, UGT1A1 was the most active. Furthermore, the variants of these isoforms showed decreased SN-38 glucuronidation activity. In our study, we compared the different variants of UGT1As, such as UGT1A1.6, UGT1A1.7, UGT1A1.27, UGT1A1.35, UGT1A7.3, UGT1A8.4, UGT1A10M59I, and UGT1A10T202I, to determine the differences in the reduction of glucuronidation. Our study elucidates the relationship between UGT1A variants and the level of glucuronidation associated with each variant. Therefore, testing can be done before the initiation of irinotecan treatment to predict potential toxicities and adverse effects.